The study's findings were published online in December 2009 ahead of print in the Journal of Nuclear Medicine (JNM). Current imaging technologies miss up to 30 percent of breast cancers and cannot differentiate malignant tumors from benign tumors, thus requiring invasive biopsies. Approximately 5.6 million biopsies performed in the United States find only benign lesions. These biopsies cause considerable stress for the patients and have significantly high costs.
"The challenge has been to develop an imaging agent that will target a specific, fingerprint biomarker that visualizes malignant breast lesions early and reliably,” said Mathew Thakur, Ph.D., professor of radiology at Jefferson Medical College of Thomas Jefferson University (Philadelphia, PA, USA) and director of Radiopharmaceutical Research and Nuclear Medicine Research.
Dr. Thakur and colleagues evaluated an agent called 64Cu-TP3805, which is used to evaluate tumors via positron emission tomography (PET) imaging. 64Cu-TP3805 detects breast cancer by finding a biomarker called VPAC1, which is overexpressed as the tumor develops. The researchers compared the images using that agent with images using the gold standard imaging agent, 18F-FDG. They used MMTVneu mice, which are mice that develop breast tumors spontaneously, similar to humans. The mice first received a PET scan using the 18F-FDG. Then they received a computed tomography (CT) scan, and then they received another PET scan using 64Cu-TP3805.
Ten tumors were detected on the mice. Four tumors were detected using both 18F-FDG and 64Cu-TP3805, and four additional tumors were found with 64Cu-TP3805 only. All eight of these tumors overexpressed the VPAC1 oncogene on tumor cells and were malignant by histology. The remaining two tumors were benign and were detected only with 18F-FDG. They did not express the VPAC1 oncogene, and therefore were not detected by the 64Cu-TP3805.
"If this ability of 64Cu-TP3805 holds up in humans, then in the future, PET scans with 64Cu-TP3805 will significantly contribute to the management of breast cancer,” Dr. Thakur concluded.
Related Links:
Jefferson Medical College of Thomas Jefferson University
